NCT06845280

Brief Summary

Original value: Shock is an important cause of mortality in intensive care units (ICU). Determining whether shock patients will benefit from (intravenous) IV fluid therapy is possible by fluid responsiveness parameters/tests. More than half of the patients being monitored for shock in the ICU are not fluid responders. Especially in patients who do not have the desired response despite appropriate shock treatment for the first 6 hours, continuing IV bolus fluid treatments without performing fluid responsiveness tests may cause an increase in mortality due to hypervolemia and organ edema. Today, these tests can be measured with transpulmonary thermodilution (TPTD) devices. Calibration, installation and evaluation of the device requires expert personnel and its use can cause a significant increase in intensive care workload. Instead of this minimal invasive approach, the respiratory variability of maximal aortic blood flow rate (ΔVaortmax), which can be obtained non-invasively with the use of bedside ultrasonography (USG), can be used as a fluid responsiveness parameter. There is no study on the value of this parameter in adult intensive care patients. Revealing the importance of this parameter as a fluid responsiveness parameter may pave the way for ultrasonography devices, which are already in use with other indications, to be used as an important advanced hemodynamic monitoring tool. For this purpose, this prospective observational study was planned. Method: This study was planned to be conducted on non-pregnant shock patients who are greater than 18 years and who were admitted to Medical ICU of Ankara University Faculty of Medicine, Department of Internal Medicine Division of Intensive Care. It was planned to establish the TPTD system, which is a standard practice in patients whose shock symptoms did not improve and whose lactate level did not decrease despite appropriate fluid, vasopressor and standard intensive care applications for the first 6 hours, and to compare the fluid responsiveness parameters obtained from this TPTD system with the ΔVaortmax obtained by bedside USG. Within the scope of a 6-12 month study period, it is planned to perform advanced hemodynamic monitoring with TPTD in 60 patients and to compare the obtained measurements with ΔVaortmax measurements with bedside USG. In order to carry out the project, a TPTD device and its thermodilution catheters as well as a standard ultrasonography device with an echocardiography system are needed. Management: Patients who are admitted with shock to our ICU and who develop shock state during their admission will be evaluated for eligibility for the study. A TPTD system will be installed in patients eligible for the study, and a bedside USG will be performed simultaneously and fluid responsiveness and other clinical and hemodynamic data will be recorded. Data will be analyzed to evaluate whether ΔVaortmax, is a good fluid responsiveness parameter for adult shock patients and to determine a cutoff value to assign volume responsive patients. Widespread effect: With this project, USG/echocardiography devices, which are already commonly used in ICU's for various purposes, will find a new use as advanced hemodynamic monitoring tools to determine fluid responsiveness during shock states, without incurring additional risks to patiens with minimal additional costs. Importantly, this method may reduce the need for some minimally invasive methods such as transpulmonary thermodilution. The results of our project will be disseminated through oral presentations and articles.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 27, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

February 1, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

February 25, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

February 25, 2025

Status Verified

February 1, 2025

Enrollment Period

11 months

First QC Date

December 27, 2024

Last Update Submit

February 24, 2025

Conditions

Keywords

Shockintensive caretranspulmonary thermodilutionechocardiography

Outcome Measures

Primary Outcomes (1)

  • Respiratory variability of maximal aortic blood flow

    To compare respiratory variability of maximal aortic blood flow obtained by transthoracic echocardiography with fluid responsiveness parameters obtained by transpulmonary thermodilution.

    maxiumum 5 days

Secondary Outcomes (1)

  • Mortality

    Mortality event up to first month after the hemodynamic measurements will be monitored.

Study Arms (1)

Shock patients

Critically ill shock patients who require at least 0.2mcg/kg/min noradrenaline, or have lactate levels \>4 mEq/L and whose clinical tissue perfusion parameters are deteriorating despite adequate treatment for 6 hours (increasing lactate levels, mottling score, decreasing consciousness... ) will be evaluated for eligibility.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Shock patients monitored in intensive care

You may qualify if:

  • Age over 18 years old
  • Being admitted to medical intensive care unit of Ankara University Faculty of Medicine
  • Having a diagnosis of shock
  • Deteriorating shock state after the initial 6 hour despite optimal treatment
  • Patients or their relatives are required to read, understand and sign the informed consent form for participation in the study.
  • Patients who are expected to stay in intensive care for at least 48 hours

You may not qualify if:

  • The patient has an identified pregnancy or suspected pregnancy.
  • Presence of thrombocytopenia that may prevent catheter placement (platelet count less than 50 thousand/mm3 and not being able to be increased)
  • Prolongation of prothrombin time that may prevent catheter placement
  • Prolongation of activated partial thromboplastin time that may prevent catheter placement
  • Failure to provide jugular or subclavian central venous catheterization
  • Clinical conditions that prevent the insertion of an arterial thermistor catheter (edema, hematoma, thrombosis, signs of active infection in the area where the catheter will be inserted) and the inability to insert an arterial thermistor catheter
  • The patient is receiving CRRT (Continuous renal replacement therapy)/ECMO (Extracorporeal membrane oxygenation)
  • Contraindications to passive leg raising test (axial fractures, intra-abdominal hypertension, increased intra-abdominal pressure, lower extremity amputation)
  • Presence of conditions preventing bedside USG (chest wall deformity, inability to position the patient appropriately, inadequate image quality, open wound, infection or dressing on the chest wall preventing transthoracic USG)
  • Objection of patients' intensivist to enroll the patient (with a documented reason)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara University Faculty of Medicine Ibn'i Sina Hospital

Ankara, TR, 06230, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Shock

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Uğur Özdemir, Academic

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
15 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 27, 2024

First Posted

February 25, 2025

Study Start

February 1, 2025

Primary Completion

January 1, 2026

Study Completion

April 1, 2026

Last Updated

February 25, 2025

Record last verified: 2025-02

Locations